Close
  Indian J Med Microbiol
 

Figure 1: Hazard ratios (95% confidence intervals) for cardiorenal outcomes within LEADER and SUSTAIN 6 for liraglutide or semaglutide, respectively, versus placebo, by baseline body mass index group. LEADER/SUSTAIN 6 overall category based on full analysis set for the trial. *Primary MACE: Composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. †Nephropathy: new or persistent macroalbuminuria, doubling of serum creatinine, end-stage renal disease, or death from renal disease. BMI: Body mass index (in kg/m2), CI: Confidence interval, HR: Hazard ratio, Int: Interaction, MACE: Major adverse cardiovascular event

Figure 1: Hazard ratios (95% confidence intervals) for cardiorenal outcomes within LEADER and SUSTAIN 6 for liraglutide or semaglutide, respectively, versus placebo, by baseline body mass index group. LEADER/SUSTAIN 6 overall category based on full analysis set for the trial. *Primary MACE: Composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. †Nephropathy: new or persistent macroalbuminuria, doubling of serum creatinine, end-stage renal disease, or death from renal disease. BMI: Body mass index (in kg/m2), CI: Confidence interval, HR: Hazard ratio, Int: Interaction, MACE: Major adverse cardiovascular event